文献速递湿疹皮炎与荨麻疹

奥马珠单抗治疗慢性荨麻疹的药物生存率及停药相关因素:一项Meta分析

Drug Survival of Omalizumab and Factors Associated With Discontinuation in Chronic Urticaria: A Meta-Analysis.
PubMed 文献 · JAMA Dermatol · 2026-01-01

该Meta分析纳入8项观察性研究共4516例慢性荨麻疹患者,评估奥马珠单抗长期药物生存率及停药因素。中位药物生存期为3.1年,7年随访期间平均持续治疗3.75年。停药多因疾病控制良好而非不良事件,自身免疫合并症与疗效不足停药风险升高相关。

要点

  • 奥马珠单抗治疗慢性荨麻疹中位药物生存期为3.1年。
  • 停药主要因疾病控制良好,不良事件导致停药不常见。
  • 自身免疫合并症与疗效不足停药风险升高相关。

核心结论

  • 奥马珠单抗在慢性荨麻疹中显示长期药物生存率,停药更多因疾病控制而非不良事件。
  • 自身免疫合并症(主要为甲状腺相关)与药物生存率降低相关,主要因疗效不足。
  • 特应性背景与疾病控制后停药风险增加相关,提示需改进内型驱动治疗策略。

研究设计与样本

  • 系统综述与随机效应Meta分析,检索PubMed、Embase和Web of Science从建库至2026年1月20日。
  • 纳入报告奥马珠单抗停药时间或药物生存结局的观察性临床研究,共8项研究4516例慢性荨麻疹患者。
  • 使用IPDfromKM框架从已发表Kaplan-Meier曲线重建时间-事件数据,合并风险比(HRs)。

主要发现

  • 中位药物生存期为3.1年(95% CI,2.8-3.4)。
  • 7年随访期间患者平均继续治疗3.75年(95% CI,3.62-3.87)。
  • 慢性诱导性荨麻疹(伴或不伴慢性自发性荨麻疹)的7年生存率(43%-49%)高于单纯慢性自发性荨麻疹(30%)。
  • 自身免疫合并症与因疗效不足停药风险升高相关(HR,2.03;95% CI,1.20-3.41)。
  • 特应性背景与因疾病控制良好停药风险增加相关。

关键数值与推荐

  • 中位药物生存期3.1年(95% CI,2.8-3.4)。
  • 7年随访平均治疗持续时间3.75年(95% CI,3.62-3.87)。
  • 慢性诱导性荨麻疹7年生存率43%-49%,单纯慢性自发性荨麻疹30%。
  • 自身免疫合并症因疗效不足停药HR 2.03(95% CI,1.20-3.41)。

临床怎么用

  • 奥马珠单抗用于慢性荨麻疹需关注长期药物生存,停药决策应结合疾病控制情况。
  • 对合并自身免疫疾病(尤其甲状腺相关)患者,需警惕疗效不足导致的停药风险。
  • 特应性背景患者疾病控制后可能更早停药,可据此进行患者分层管理。

局限性

  • 仅纳入观察性研究,可能存在异质性和偏倚。
  • 部分研究缺乏生存数据或不足以重建生存曲线而被排除。
  • 自身免疫合并症主要为甲状腺相关,其他类型数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Omalizumab is a recommended second-line therapy for chronic urticaria (CU), yet clinical evidence regarding long-term drug survival and determinants of discontinuation remains limited. Understanding drug survival patterns may inform clinical decision-making and patient stratification. OBJECTIVE: To evaluate the long-term drug survival of omalizumab in patients with CU and identify factors associated with discontinuation. DATA SOURCES: PubMed, Embase, and Web of Science were systematically searched from database inception to January 20, 2026. STUDY SELECTION: Observational clinical studies that reported on time to discontinuation or drug survival outcomes for omalizumab in patients with CU were included. Studies lacking survival data or sufficient information for reconstruction of survival curves were excluded. DATA EXTRACTION AND SYNTHESIS: Time-to-event data were reconstructed from published Kaplan-Meier curves using a validated algorithm implemented in the IPDfromKM framework. Pooled hazard ratios (HRs) were synthesized using a random-effects meta-analysis. Analyses followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. MAIN OUTCOMES AND MEASURES: Primary outcomes included overall drug survival and reasons for discontinuation. Secondary outcomes included predictors of discontinuation, expressed as HRs with 95% CIs. RESULTS: Eight studies comprising 4516 patients with CU (3167 female individuals [70.1%]; 3276 with chronic spontaneous urticaria [CSU]) were included. The median drug survival for omalizumab was 3.1 years (95% CI, 2.8-3.4). Over a 7-year follow-up period, patients continued to receive treatment for a mean of 3.75 years (95% CI, 3.62-3.87). Long-term drug survival appeared higher in chronic inducible urticaria (with or without concomitant CSU) than in CSU alone (7-year survival, 43%-49% vs 30%). Early discontinuation was primarily due to well-controlled disease. Discontinuation due to adverse events was uncommon. Autoimmune comorbidity was associated with a higher risk of discontinuation due to lack of efficacy (HR, 2.03; 95% CI, 1.20-3.41), while an atopic background was associated with an increased risk of discontinuation due to well-controlled disease. CONCLUSIONS AND RELEVANCE: The results of this systematic review and meta-analysis suggest that omalizumab demonstrates long-term drug survival in CU, with discontinuation more often due to disease control than adverse events. Autoimmune comorbidities (mainly thyroid-related) were associated with reduced drug survival, primarily due to lack of efficacy, whereas atopic comorbidities were associated with discontinuation after disease control, underscoring the need for improved endotype-driven treatment strategies.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Altayf A, Kolkhir P, Alwefati M, et al. Drug Survival of Omalizumab and Factors Associated With Discontinuation in Chronic Urticaria: A Meta-Analysis. JAMA Dermatol. 2026. PMID: 42714921. doi:10.1001/jamadermatol.2026.2043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。